Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Gene Evolution - Fast or Slow?

Gene Evolution - Fast or Slow?

The genomes of eukaryotes are punctuated by long stretches of sequence which do not code for proteins or RNAs. Although some of these regions do contain crucial regulatory sequences, the vast majority of this DNA serves no known function. Typically, these regions of the genome are the ones in which the fastest change, in evolutionary terms, is observed, because there is typically little to no selection pressure acting on these regions to preserve their sequences.
In contrast, regions which code...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

Disorders of Leukocytes

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...

Lineage Commitment

Lineage Commitment

Commitment is the process whereby stem cells:

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026

Same author

Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma.

HemaSphere·2026

Same author

Genomic heterogeneity in primary cutaneous follicular center lymphomas reveals different clinicopathological subgroups.

HemaSphere·2026

Same author

Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025.

Cancers·2026

Same author

Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma and Tuberculosis: A Rare Association With Diagnostic and Therapeutic Challenges.

Journal of medical cases·2026

Same author

The expression of MALAT1 long non-coding RNA is associated with good prognosis in mantle cell lymphoma.

Scientific reports·2026

Search research articles

Related Experiment Video

Updated: Mar 13, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Genetic evolution in chronic lymphocytic leukaemia.

Julio Delgado¹, Neus Villamor², Armando López-Guillermo³

¹Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Calle Roselló 149-153, 08036 Barcelona, Spain; Department of Haematology, Hospital Clínic, Calle Villarroel 170, 08036 Barcelona, Spain.

Best Practice & Research. Clinical Haematology

|October 16, 2016

Summary

Next-generation sequencing reveals key genomic and epigenomic drivers of chronic lymphocytic leukaemia (CLL). Understanding these drivers offers new therapeutic targets and strategies to prevent treatment resistance in CLL patients.

Keywords:

CLL Clonal evolution Epigenomics Genomics NGS Non-coding

More Related Videos

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

Related Experiment Videos

Last Updated: Mar 13, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

Area of Science:

Oncology
Genomics
Epigenetics

Background:

Chronic lymphocytic leukaemia (CLL) is a malignancy with complex genomic and epigenomic underpinnings.
Recent advancements in sequencing technologies have enabled deeper investigation into the molecular basis of CLL.

Purpose of the Study:

To comprehensively understand the genomic, epigenomic, and transcriptomic landscape of CLL.
To identify novel drivers and pathways involved in CLL pathogenesis.
To explore potential therapeutic strategies based on molecular findings.

Main Methods:

Utilizing next-generation sequencing (NGS) for comprehensive genomic, epigenomic, and transcriptomic analysis.
Analyzing mutations in both coding and non-coding regions.
Investigating signalling pathways implicated in CLL.

Main Results:

Identification of novel genetic drivers, including non-coding mutations.
Elucidation of signalling pathways previously unappreciated in CLL.
Establishment of the cellular origins of CLL through epigenomic and transcriptomic data.
Discovery of potential therapeutic targets for CLL management.

Conclusions:

Next-generation sequencing provides critical insights into CLL biology.
Targeting identified drivers and pathways may lead to novel therapeutic interventions.
Early detection of subclones could prevent disease refractoriness and improve patient outcomes.